Home›OB/GYN & Women's Health› Single-cell RNA sequencing reveals trophoblast and immune mechanisms in preeclampsia pathogenesis
Single-cell RNA sequencing reveals trophoblast and immune mechanisms in preeclampsia pathogenesisNew Sequencing Methods Reveal Hidden Mechanisms of Preeclampsia
Frontiers in MedicinePublished June 12, 2026Study authors: Xiaojing Pan, Ting LuoDOI ↗Editorial oversight: Dr. Sofia Müller, MD · Lifespan & Whole-Person Care
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Interpret scRNA-seq findings as exploratory; clinical validation of identified molecules is needed before application.
This systematic review synthesizes single-cell RNA sequencing (scRNA-seq) studies to elucidate cellular and molecular mechanisms underlying preeclampsia (PE). The review focuses on trophoblast dysfunction and immune dysregulation at the maternal-fetal interface, comparing scRNA-seq with bulk sequencing methods.
Key findings include impaired trophoblast differentiation, invasion, and accelerated senescence, with regulatory molecules BHLHE40, NDRG1, and DAB2 implicated. Immune dysregulation involves altered NK cell subsets, macrophage polarization, and disruption of immune tolerance mediated by HLA-F and JUNB. These insights offer potential for novel biomarkers and disease subtyping.
Limitations are not reported in the review. The clinical utility of identified molecules as biomarkers or therapeutic targets is not yet established. The review underscores scRNA-seq as a discovery tool, but further studies are needed to translate these findings into clinical practice.
Practice relevance: scRNA-seq may enable precision medicine in preeclampsia by identifying biomarkers and constructing predictive models, but current evidence is preliminary.
How this fits prior evidence
This systematic review extends prior coverage by providing a molecular-level view of preeclampsia pathogenesis, complementing earlier findings on lipid profiles and homocysteine screening. It aligns with the call for precision interventions by identifying specific trophoblast and immune pathways, potentially enabling endotype-based subtyping. However, unlike prior reviews on ADMA or hypertriglyceridemia, this work does not address therapeutic targets directly.
Researchers used a specialized technique called single-cell RNA sequencing to study the placenta and decidua in women with preeclampsia. This method allows scientists to look at individual cells rather than looking at a large group of tissue all at once. The study focused on how these cells behave and change during the progression of the condition.
The findings show that certain cells, known as trophoblasts, do not function correctly in cases of preeclampsia. These cells showed signs of aging too quickly and had trouble moving or growing properly. The researchers also found evidence of immune system issues at the boundary between the mother and the baby. This includes changes in specific types of immune cells like NK cells and macrophages.
While these findings identify several molecules that might be involved in the disease, it is important to note that this research is currently for discovery purposes. The study does not yet prove that these specific molecules can be used as reliable tests or treatments. These results are a step toward creating better ways to identify different types of preeclampsia and finding new targets for future medical care.
What this means for you:
New sequencing technology helps identify cellular changes in preeclampsia, though clinical uses are not yet proven.
Common questions
What did this research find about how preeclampsia affects the placenta?
The study found that trophoblast cells in the placenta show signs of impaired growth and accelerated aging. These cells also have trouble with proper differentiation and invasion. The researchers identified specific molecules, such as BHLHE40, NDRG1, and DAB2, that are linked to these issues in the placental tissue.
How does preeclampsia affect the immune system during pregnancy?
The research shows a disruption in immune tolerance at the maternal-fetal interface. This includes changes in NK cell subsets and macrophage polarization. These immune issues are linked to specific factors like HLA-F and JUNB, which may play a role in how the body responds during preeclampsia.
Can these findings be used for new treatments or tests immediately?
Not yet. While the study identifies several molecules that could eventually become biomarkers or targets for treatment, their clinical use is not established. This research is currently a tool for discovery to help scientists understand the disease better and develop future medical options.
Preeclampsia (PE) is a pregnancy-specific multisystem disorder and a leading cause of maternal and perinatal morbidity and mortality worldwide. Despite the widely accepted two-stage model involving placental dysfunction and maternal systemic inflammation, the precise cellular and molecular mechanisms underlying its pathogenesis remain incompletely understood. In recent years, single-cell RNA sequencing (scRNA-seq) has emerged as a transformative technology capable of resolving transcriptional heterogeneity at unprecedented resolution, offering new insights into the complex cellular landscape of the maternal-fetal interface. This review systematically summarizes the application of scRNA-seq in advancing the understanding of PE pathogenesis. We first introduce the technical principles and advantages of scRNA-seq over bulk sequencing methods. Subsequently, we highlight key findings from scRNA-seq studies of the normal placenta and decidua, establishing a reference for cellular composition and trophoblast differentiation trajectories. We then focus on studies of PE placentas, which have revealed distinct dysfunction in trophoblast subpopulations—including impaired differentiation, invasion, and accelerated senescence—and have identified novel regulatory molecules such as BHLHE40, NDRG1, and DAB2. Additionally, we discuss scRNA-seq-derived insights into immune dysregulation at the maternal-fetal interface, including altered NK cell subsets, macrophage polarization, and disruption of immune tolerance mediated by molecules such as HLA-F and JUNB. Finally, we explore the translational potential of scRNA-seq in identifying novel biomarkers, constructing predictive models, and enabling disease subtyping for precision medicine. By capturing cell-specific transcriptional changes, scRNA-seq provides a powerful framework for deciphering the complexity of PE and holds promise for improving its prediction, diagnosis, and therapy.
